ArticleMolecular & cellular proteomics : MCP2011
Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease.
Article in Molecular & cellular proteomics : MCP, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells.Frontiers in immunology · 2021Review
- Applications of Protein Microarrays in Biomarker Discovery for Autoimmune Diseases.Frontiers in immunology · 2021Review
- Developments and Applications of Functional Protein Microarrays.Molecular & cellular proteomics : MCP · 2020Review
- Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens.Journal of the American Society of Nephrology : JASN · 2019Article
- Precision annotation of digital samples in NCBI's gene expression omnibus.Scientific data · 2017Article
- Assessment of Circulating Protein Signatures for Kidney Transplantation in Pediatric Recipients.Frontiers in medicine · 2017Article
- Unraveling the Role of Allo-Antibodies and Transplant Injury.Frontiers in immunology · 2016Review
- Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management.Drugs · 2015Review
- Computational Models for Transplant Biomarker Discovery.Frontiers in immunology · 2015Review
- Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus.PloS one · 2015Article
- A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.Science translational medicine · 2014Article
- Moving beyond HLA: a review of nHLA antibodies in organ transplantation.Human immunology · 2013Review
- Immune response profiling identifies autoantibodies specific to Moyamoya patients.Orphanet journal of rare diseases · 2013Article
- Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.PloS one · 2013Article
- Applications of translational bioinformatics in transplantation.Clinical pharmacology and therapeutics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Biomarkers for early detection of chronic kidney disease are needed, as millions of patients suffer from chronic diseases predisposing them to kidney failure. Protein microarrays may also hold utility in the discovery of auto-antibodies in other conditions not commonly considered auto-immune diseases. We hypothesized that proteins are released as a consequence of damage at a cellular level during end-organ damage from renal injury, not otherwise recognized as self-antigens, and an adaptive humoral immune response to these proteins might be detected in the blood, as a noninvasive tracker of this injury. The resultant antibodies (Ab) detected in the blood would serve as effective biomarkers for occult renal injury, enabling earlier clinical detection of chronic kidney disease than currently possible, because of the redundancy of the serum creatinine as a biomarker for early kidney injury. To screen for novel autoantibodies in chronic kidney disease, 24 protein microarrays were used to compare serum Ab from patients with chronic kidney disease against matched controls. From a panel of 38 antigens with increased Ab binding, four were validated in 71 individuals, with (n=50) and without (n=21) renal insufficiency. Significant elevations in the titer of novel auto-Ab were noted against angiotensinogen and PRKRIP1 in renal insufficiency. Current validation is underway to evaluate if these auto-Ab can provide means to follow the evolution of chronic kidney disease in patients with early stages of renal insufficiency, and if these rising titers of these auto-Ab correlate with the rate of progression of chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.